New strategies in patients refractory to reversible EGFR-TKIs

Date 01 October 2012
Event ESMO Congress 2012
Session A patient with EGFR mutation who progresses to reversible EGFR TKI: What should we do?
Topics Cytotoxic agents
Non-small-cell lung cancer
Biological therapy
Presenter Maria Teresa Moran Bueno
Authors M.T. Moran Bueno
  • Medical Oncology, Hospital Universitari Germans Trias i Pujol, 08916 - Badalona/ES